LY2405319 is another engineered FGF21 protein that is proven to be effective in a randomized clinical trial in obesity and type 2 diabetes patients, such as reducing body weight, fasting triglycerides, and insulin levels.121. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.